Kala Pharmaceuticals, Inc. (KALA)
Stock Price:
$6.44 USD
0.16 (2.55%)
Updated Oct 28, 2020 9:51 AM EDT - Market open
Key Info
| Market Cap |
361.03M |
| Revenue (ttm) |
4.54M |
| Net Income (ttm) |
-90.40M |
| Shares Out |
56.06M |
| EPS (ttm) |
-2.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$6.44 |
| Previous Close |
$6.28 |
| Change ($) |
0.16 |
| Change (%) |
2.55% |
| Day's Open |
6.80 |
| Day's Range |
6.41 - 7.00 |
| Day's Volume |
1,645,708 |
| 52-Week Range |
3.45 - 14.68 |
More Stats
| Market Cap |
361.03M |
| Enterprise Value |
264.93M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
56.06M |
| Float |
48.42M |
| EPS (basic) |
-2.27 |
| EPS (diluted) |
-2.18 |
| FCF / Share |
-1.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.53M |
| Short Ratio |
4.43 |
| Short % of Float |
13.48% |
| Beta |
0.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
79.61 |
| PB Ratio |
3.37 |
| Revenue |
4.54M |
| Operating Income |
-83.17M |
| Net Income |
-90.40M |
| Free Cash Flow |
-81.57M |
| Net Cash |
96.09M |
| Net Cash / Share |
1.71 |
| Gross Margin |
89.66% |
| Operating Margin |
-1,833.94% |
| Profit Margin |
-1,993.40% |
| FCF Margin |
-1,798.57% |
| ROA |
-24.50% |
| ROE |
-95.15% |
| ROIC |
-58.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.71*
(206.06% upside)
Low
10.0
Current: $6.44
High
39.0
Target: 19.71
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 6.07 | - | - | - | 0.05 |
| Gross Profit | 4.07 | - | - | - | 0.05 |
| Operating Income | -88.22 | -64.72 | -39.88 | -32.67 | -15.95 |
| Net Income | -94.35 | -66.74 | -42.21 | -33.17 | -16.68 |
| Shares Outstanding | 34.21 | 26.75 | 11.38 | 1.18 | 1.12 |
| Earnings Per Share | -2.76 | -2.49 | -3.71 | -28.07 | -14.89 |
| Operating Cash Flow | -92.72 | -54.12 | -34.10 | -27.35 | -15.09 |
| Capital Expenditures | -1.34 | -1.58 | -0.48 | -0.15 | -0.25 |
| Free Cash Flow | -94.06 | -55.70 | -34.58 | -27.50 | -15.34 |
| Cash & Equivalents | 98.03 | 183 | 115 | 45.58 | 5.87 |
| Total Debt | 101 | 99.44 | 18.65 | 9.65 | 9.80 |
| Net Cash / Debt | -3.15 | 83.66 | 96.05 | 35.93 | -3.93 |
| Assets | 154 | 221 | 117 | 46.33 | 8.45 |
| Liabilities | 125 | 116 | 26.87 | 15.70 | 14.24 |
| Book Value | 29.69 | 105 | 89.68 | -87.76 | -56.66 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kala Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
136 |
| CEO |
Mark T. Iwicki |
Stock Information
| Ticker Symbol |
KALA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KALA |
| IPO Date |
July 20, 2017 |
Description
Kala Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.